EUVIMEDEUVIMED entdecken
Open Access

Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar

Adil Ali Shakur, Raj Kumar, Raushan Kumar Ranjan, Saajid Hameed iD, Lalit Mohan

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders · 2026-05 · 19

DOI: 10.1177/11795441261448563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, online erschienen am 18.05.2026. Verfasst von Adil Ali Shakur und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Patna, India. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologics have revolutionized the treatment of autoimmune rheumatologic diseases, but data on their real-world use and safety in resource-limited settings like Bihar, India, are scarce.

Objectives

This study aimed to evaluate the prescription patterns and safety profile of biologic disease-modifying antirheumatic drugs (b-DMARDs) in patients with rheumatoid arthritis (RA) at a tertiary care hospital in Bihar.

Design

A prospective, observational cohort study conducted over 12 months.

Methods

A total of 120 adult patients with RA prescribed b-DMARDs were enrolled. Data on demographic, clinical characteristics, and treatment details were collected. Disease activity (DAS-28-CRP) and functional status (HAQ-DI) were assessed at baseline and 6 months. Adverse events, particularly infections, were recorded and analysed using multivariable logistic regression to identify risk factors.

Results

Biologicals were prescribed in 14.93% patients with RA. Adalimumab (49.17%) was the most prescribed b-DMARD, followed by etanercept (28.33%). Methotrexate was the most common concomitant conventional DMARD (85.83%). All b-DMARDs significantly improved DAS-28-CRP and HAQ-DI scores ( P < .0001), with adalimumab showing the greatest improvement. Infliximab had the highest infection rate (53.33%), whereas etanercept had the lowest (14.70%). Regression analysis identified infliximab use (adjusted odds ratio [aOR]: 3.27), concomitant corticosteroid use (aOR: 2.74), and the presence of comorbidities (aOR: 2.13) as significant independent risk factors for infection.

Conclusion

Biologic disease-modifying antirheumatic drugs are effective in RA, but infection risks vary. Adalimumab and etanercept demonstrated favourable efficacy and safety profiles, respectively. Treatment decisions should be personalized, considering drug-specific risks, corticosteroid co-therapy, and patient comorbidities, especially in resource-constrained settings.

Schlagwörter

Stichwörter der Autor:innen

DMARDsautoimmune rheumatologic diseasesbiologicsinfection riskprescription patternsrheumatoid arthritis

Autor:innen und Institutionen

  • Department of Pharmacology, Indira Gandhi Institute of Medical Sciences, Patna, India.
  • Department of Physical Medicine and Rehabilitation, Indira Gandhi Institute of Medical Sciences, Patna, India.

ORCID-Profile: Saajid Hameed

Zitieren

APA

Shakur, A. A., Kumar, R., Ranjan, R. K., Hameed, S., & Mohan, L. (2026). Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 19. https://doi.org/10.1177/11795441261448563

Vancouver

Shakur AA, Kumar R, Ranjan RK, Hameed S, Mohan L. Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2026;19. doi:10.1177/11795441261448563

BibTeX
@article{Shakur2026,
  author = {Shakur, Adil Ali and Kumar, Raj and Ranjan, Raushan Kumar and Hameed, Saajid and Mohan, Lalit},
  title = {Prescription Pattern and Safety of Biologics in Autoimmune Rheumatologic Diseases in Tertiary Care Hospital of Bihar},
  journal = {Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders},
  year = {2026},
  volume = {19},
  doi = {10.1177/11795441261448563}
}
Kostenlos starten →